Biomarkers Characterization of CTCs in Breast Cancer
Biomarkers Characterization of CTCs in Breast Cancer
Our findings exhibit the heterogeneity of biomarker distribution in CTCs and a lack of correlation with the primary tumor biomarker profile before and after chemotherapy. The lack of an association between HR, HER2, and TOP2A status in CTCs and BC subtypes may contribute to diversity in gene expression patterns and clinical outcomes within BC subtypes. Biomarker characterization in CTCs might become a useful tool for selecting patients for tailored therapies and target drug development. However, these findings should be validated in a larger cohort of patients.
Conclusions
Our findings exhibit the heterogeneity of biomarker distribution in CTCs and a lack of correlation with the primary tumor biomarker profile before and after chemotherapy. The lack of an association between HR, HER2, and TOP2A status in CTCs and BC subtypes may contribute to diversity in gene expression patterns and clinical outcomes within BC subtypes. Biomarker characterization in CTCs might become a useful tool for selecting patients for tailored therapies and target drug development. However, these findings should be validated in a larger cohort of patients.
Source...